Teva Pharmaceutical Industries has collaborated with Intel Corporation to develop a wearable device and machine learning platform that can be used by patients suffering from Huntington disease (HD).

This platform will enable continuous monitoring and analysis of important symptoms that impact daily living, thereby helping to gain a better understanding of disease progression to improve treatment.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The collaboration will see deployment of the new technology platform in a sub-study within the ongoing Phase 2 Open-Pride HD Study.

"This platform will enable continuous monitoring and analysis of important symptoms that impact daily living, thereby helping to gain a better understanding of disease progression to improve treatment."

Under this study, patients will have to use a smartphone and wear a smartwatch equipped with sensing technology that will measure their general functioning and movement.

The data gathered will be wirelessly sent to a cloud-based platform specifically developed by Intel to analyse data from wearable devices.

See Also:

The data will be translated by proprietary algorithms in near real-time, into objective scores of motor symptom severity.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Teva global research and development president and chief scientific officer Michael Hayden said: "The aim of this important project is to provide continuous objective data on the impact of Huntington disease on the patient, and, by extension, a clear understanding of the impact of treatment on patients' quality of life.

"Current measurement of symptoms is largely based on observation when the patient sees the doctor.

“This technology now provides us with an opportunity to have continuous monitoring.

"This unique technology could complement future trials in HD.”

The study will commence by the end of the year and will take place in centres in the US and Canada.